Home › Urolithiasis › NCT06003348
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
RecruitingPhase 4
Who can join
Ages 21 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: \- Calcium Phosphate stone formers Exclusion Criteria: * History of recurrent urinary tract infections * Chronic diarrhea * Estimated Glomerular Filtration Rate (eGFR) \< 45 ml/min/1.73 m2 * History of primary hyperparathyroidism * Hypokalemia * Hyperkalemia * Pregnancy
About the study
This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
What is being tested
- OHCit- standard dose (dietary supplement)
- Potassium Citrate (drug)
- Placebo (drug)
- OHCit- low dose (dietary supplement)
Sponsor: University of Texas Southwestern Medical Center · Participants: 25 · Started: Dec 13, 2023
Contact the study team
- NAIM M MAALOUF, MD · Phone: 214/648-2954
- Miranda King · Phone: 2146482117
Official record on ClinicalTrials.gov — NCT06003348
Locations in the U.S.
| Texas | UT Southwestern Medical Center, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.